Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Development of glycan-targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment

Fig. 3

STn-targeted nanoparticles containing dsRNA against galectin-3 and/or ST6GalNAc-I increase gastric cancer cells susceptibility to 5-FU in vitro. SRB assay showing the viability of MKN45-Mock, MKN45-ST6GalNAc-I, HUVEC and CHO cells under the treatment with sTn-targeted NP loaded with dsRNA-galectin-3 (A, B) or sTn-targeted NP loaded with dsRNA-ST6GalNAc-I (C, D). E SRB assay showing the viability of MKN45-ST6GalNAc-I cells in the presence of 10 nM of sTn-targeted NP loaded with dsRNA-galectin-3, dsRNA-ST6GalNAc-I or dsRNA-random, or a (1:1) combination of dsRNA-ST6GalNAc-I and dsRNA-galectin-3, in the presence of 5-FU (ranging from 2 to 0.001 mM). Results are presented as a percentage of viable cells relative to control (cells with no NPs or 5-FU treatment). F The average of IC50 values. Data are the mean ± SEM, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001

Back to article page